GLPG Galapagos NV

Important update to Galapagos’ invitation to its ordinary and extraordinary shareholders’ meetings

Important update to Galapagos’ invitation to its ordinary and extraordinary shareholders’ meetings

Mechelen, Belgium; 17 April 2020, 01.15 CET; regulated information – In light of the ongoing COVID-19 pandemic, Galapagos NV (Euronext & NASDAQ: GLPG) will hold its shareholders’ meetings behind closed doors, with shareholder participation in advance only.

Out of safety precautions against the COVID-19 pandemic, and in accordance with the Royal Decree No. 4 under special powers published on 9 April 2020, the physical presence of shareholders, proxyholders, holders of subscription rights or other persons otherwise entitled to attend the shareholders’ meeting will be prohibited at Galapagos’ annual (ordinary) and extraordinary shareholders’ meetings scheduled for Tuesday 28 April 2020 at 2:00 p.m. (CET).

Shareholders are kindly invited and strongly encouraged to vote prior to the meetings, either by voting form or by proxy.

Please note the following alternative arrangements for the meetings:

      (1)   Proxies can only be granted to the general counsel. An updated proxy form is available on our website, under the tab “Investors > Shareholder Information > Shareholders’ Meetings > Proxy form”.

             

            If a proxy has already been received on the date and time of this press release in which a different proxy holder is appointed, the votes or abstentions will still be taken into account if the proxy contains specific voting instructions, and without this other proxy holder having to be present at the meetings;

             

      (2)   Voting forms and proxies must reach Galapagos before or on or 24 April 2020 at midnight CET at the latest.

             

            An updated voting form is available on our website, under the tab “Investors > Shareholder Information > Shareholders’ Meetings > Voting form”. If a voting form has already been received on the date and time of this press release, the votes or abstentions will still be taken into account;

             

  1. Only written questions may be submitted and must reach Galapagos before or on or 24 April 2020 at midnight CET at the latest. Answers will be published on our website at the latest prior to the vote;

     
  2. Both meetings will be held at the offices of Van Halteren notaires - notarissen, de Lignestraat 13, 1000 Brussels, instead of Galapagos’ registered office.

             

It is strongly recommended to use e-mail () only for all communications regarding the shareholders’ meetings, as postal services may be disrupted due to the pandemic. Please also note that the above mentioned Royal Decree exempts us from keeping the (updated) documents pertaining to the meetings physically available at our registered office or providing them by post.

The above mentioned arrangements prevail over the arrangements with the same subject as described in the convening notice, published on our website on 27 March 2020. An updated attendance notification form, taking into account that only voting prior to the meetings is allowed, is available on our website, under the tab “Investors > Shareholder Information > Shareholders’ Meetings > Attendance notification form”.

An updated convening notice and other documents pertaining to the shareholders’ meetings, including all details regarding the meetings’ procedures, can be consulted on our website, at . The Investor Relations team contacts below can assist with completion of shareholder participation in advance of the meetings.

Galapagos would like to thank its shareholders for their support during this unprecendented situation. For a letter from our CEO addressing the COVID-19 pandemic and its impact on Galapagos, please visit .

About Galapagos

Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises discovery through Phase 3 programs in inflammation, fibrosis, osteoarthritis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at .

Contact

Investors:

Elizabeth Goodwin

VP Investor Relations

Sofie Van Gijsel

Director Investor Relations

5

Media:

Carmen Vroonen

Senior Director Communications & Public Affairs

Evelyn Fox

Director Communications

9

Forward-looking statements

This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.

Disclaimer

The contents of our website, including the annual report for the financial year 2019, and any other website that may be accessed from our website, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.



 

 

Attachment

EN
16/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Galapagos NV

Guy Sips ... (+6)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Livio Luyten
  • Michiel Declercq
  • Wim Lewi
Jacob Mekhael
  • Jacob Mekhael

Galapagos Media reports Paul Stoffels behind non-binding offer for cel...

According to media reports, Paul Stoffels, Galapagos' previous CEO, has assembled a group of investors to bid for the company's cell therapy business. After joining Galapagos in 2022, Paul Stoffels pivoted the company towards cell therapies and focussed the company's efforts on de-centralised CAR-T manufacturing as a way to broaden access to such treatments. Following his resignation earlier this year, he now has placed a non-binding offer for the cell therapy business which is under strategic r...

Guy Sips ... (+7)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Michiel Declercq
  • Thomas Couvreur
  • Wim Lewi
Jacob Mekhael
  • Jacob Mekhael

Galapagos Receives non-binding offers for cell therapy business

Galapagos announced that it has received a limited number of non-binding offers from consortia, predominantly comprised of financial investors, to acquire the cell therapy business. The deadline for potential bidders to put forward binding, fully-financed, offers is in the coming weeks. The company will make an announcement on the outcome of the review of strategic alternatives for the cell therapy business no later than its 3Q25 update on 5 November 2025. € 37 TP and ACCUMULATE reiterated.

 PRESS RELEASE

Galapagos Provides Update on Strategic Alternatives for Its Cell Thera...

Galapagos Provides Update on Strategic Alternatives for Its Cell Therapy Business   Mechelen, Belgium; October 1, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and its Board of Directors today issued the following statement: On May 13, 2025, Galapagos announced that its Board of Directors (the “Board”) had decided to explore all strategic alternatives for its cell therapy business (the “Cell Therapy Business”), including a potential divestiture of the Cell Therapy Business, with the goal of preserving shareholder value. As part of its review of strategic alternatives, over ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch